Switzerland secures three million doses of Pfizer/BioNTech vaccine
The Pfizer/BioNTech employs the novel mRNA technology.
Keystone / Biontech Se / Handout
Switzerland has signed an agreement with a third manufacturer of Covid-19 vaccines for three million doses. A contract has been signed with Pfizer and BioNTech, the co-producers of the mRNA vaccine, pending safety approval from the health regulator Swissmedic.
This content was published on
2 minutes
swissinfo.ch/mga
Português
pt
Suíça obtém três milhões de doses da vacina Pfizer/BioNTech
Some 4.5 million doses of another vaccine have already been agreed with United States pharma company Moderna and another 5.3 million doses from the British-Swedish firm AstraZeneca. The government said on MondayExternal link that membership of the World Health Organization COVAXExternal link initiative grants vaccine coverage to 20% of the Swiss population.
The Pfizer/BioNTech vaccine would require two doses per person, meaning the initial supply would cover 1.5 million people.
In a press release the government said “the quality, safety and efficacy of Covid-19 vaccines are crucial. They must be approved by Swissmedic and recommended by the Federal Office of Public Health before being used”.
Earlier this month Swissmedic said it was still waiting for important data on safety, efficacy and quality from all three manufacturers.
Free of charge
Switzerland has set aside CHF400 million ($448 million) to secure supplies of vaccines. Vaccines will be offered free of charge with priority given to the most vulnerable groups and health workers. The army will be deployed to ensure stockage and distribution and to set up vaccination centres.
The government said on Monday that it was still in discussions with various other vaccine manufacturers.
“Since it is not yet clear which vaccines will prevail, it is targeting a number of SARS-CoV-2 vaccines based on different technologies (mRNA, protein-based and vector-based),” it said.
Also on Friday, Swissmedic said it had received an application from a vaccine developed by Janssen Pharmaceutical, a division of US firm Johnson & Johnson. The vaccine candidate Ad26.COV2.Sis a recombinant viral-vector vaccine based on a human adenovirus.
Swissmedic said this is the fourth vaccine it is reviewing under its “rolling procedure” that allows manufacturers to submit the results of test studies in stages.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Is artificial intelligence an advantage or a disadvantage for workers?
What is your experience with AI at work? Have you already used it? Has it helped you work better? Or has it caused you more stress, more work or caused you to lose your job? Tell us about your experiences!
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
Incomplete data stalls Swiss authorisation of Covid-19 vaccines
This content was published on
Switzerland’s medical regulator says it lacks the necessary information to sign off on three different vaccines ordered by the government.
This content was published on
With a death toll of over 5,000, Switzerland (population 8.5 million) expects to launch its coronavirus vaccination campaign in early January.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.